| Literature DB >> 34657594 |
Haniyeh Khalili1, Shahin Najar-Peerayeh1, Mona Mahrooghi1, Parvin Mansouri2, Bita Bakhshi3.
Abstract
BACKGROUND: The most common clinical manifestations of Staphylococcus aureus strains in the community are skin and soft-tissue infections. S. aureus could colonize the body sites and complicate the pathogenesis of skin diseases. S. aureus colonization is a risk factor for severe conditions such as bone and joint infections, pneumonia, bacteremia, and endocarditis. This study aimed to investigate the prevalence of S. aureus strains in skin and soft tissue infections and other skin disorders in patients referring to dermatology clinics and to evaluate the antibiotic resistance pattern and molecular characteristics of S. aureus isolates.Entities:
Keywords: Biofilm; CA-MRSA; HA-MRSA; Skin and soft tissue
Mesh:
Substances:
Year: 2021 PMID: 34657594 PMCID: PMC8521987 DOI: 10.1186/s12866-021-02340-w
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Demographic characteristics of the two patient groups
| Characteristics | Infectious Group | Non-infectious Group | Total | |
|---|---|---|---|---|
| Total patients | 67(28.63%) | 167(71.36%) | 234(100%) | – |
| Female /Male | 46/21 | 73/94 | 119/115 | .001,1.571(1.240–1.989) |
| Median age years | 23.5 | 21.7 | 22.3 | – |
| Infant (≤2) | 11(16.4%) | 44(26.3%) | 55(23.5%) | .105,0.623(0.342–1.132) |
| Children (3–18) | 22(32.8%) | 54(32.3%) | 76(32.4%) | .941,1.015(0.676–1.525) |
| Adults (18<) | 34(50.7%) | 69(41.3%) | 103(44%) | .189,1.228(0.912–1.653) |
| Patients with | 30(44.7%) | 75(44.9%) | 105(44.8%) | .985,0.997(0728–1.366) |
| Female /Male | 20/10 | 34/41 | 54/51 | .048,1.471(1.031–2.097) |
| Median age years | 24.2 | 22.6 | 23.4 | – |
| Infant (≤2) | 6(20%) | 20(26.6%) | 26(24.7%) | .475,0.750(0.334–1.683) |
| Children (3–18) | 9(30%) | 20(26.6%) | 29(37.6%) | .730,1.125(0.580–2.183) |
| Adults (18<) | 15(50%) | 35(46.6%) | 50(47.6%) | .757,1.071(0.696–1.650) |
Fig. 1Antibiotic resistance pattern of S. aureus strains isolated from infectious and non-infectious lesions. L: Linezolid, Mu: Mupirocin, C: Chloramphenicol, AK: Amikacin, FOX: Cefoxitin, T: Tetracycline, PG: Penicillin, CIP: Ciprofloxacin, GM: Gentamicin, SXT: Trimethoprim/Sulfamethoxazole, E: Erythromycin, CD: Clindamycin, RA: Rifampin
Prevalence of antibiotics resistance among MRSA and MSSA strains from the two groups of lesions
| MRSA | MSSA | |||||||
|---|---|---|---|---|---|---|---|---|
| Infectious Group | Non-infectious Group | χ | Total | Infectious Group | Non-infectious Group | χ | Total | |
| L | 3(18.7%) | 8(32%) | .990 | 11(18.6%) | 2(14.2%) | 4(12.5%) | .869 | 6(13.3%) |
| Mu | 1(6.2%) | 12(27.9%) | .074 | 13(22%) | 3(21.4%) | 6(18.7%) | .833 | 9(19.5%) |
| C | 0 | 2(4.6%) | .278 | 2(3.3%) | 0 | 0 | – | 0 |
| AK | 2(12.5%) | 8(18.6%) | .578 | 10(16.9%) | 0 | 1(3.1%) | .504 | 1(2.1%) |
| T | 8(50%) | 13(30.2%) | .159 | 21(35.5%) | 5(35.7%) | 8(25%) | .458 | 13(28.2%) |
| PG | 16(100%) | 39(90.6%) | .206 | 55(93.2%) | 14(100%) | 29(90.6%) | .236 | 43(93.4%) |
| CIP | 2(12.5%) | 3(6.9%) | .498 | 5(8.7%) | 0 | 1(3.1%) | .504 | 1(2.1%) |
| GM | 1(6.2%) | 4(9.3%) | .708 | 5(8.7%) | 0 | 0 | – | 0 |
| SXT | 7(43.7%) | 10(23.2%) | .122 | 17(28.8%) | 1(7.1%) | 2(6.2%) | .910 | 3(6.5%) |
| E | 8(50%) | 16(37.2%) | .374 | 24(40.6%) | 5(35.7%) | 13(40.6%) | .754 | 18(39.1%) |
| CD | 11(68.7%) | 28(65.5%) | .793 | 37(62.7%) | 2(14.2%) | 9(28.1%) | .311 | 11(23.9%) |
| RA | 6(37.5%) | 15(34.8%) | .852 | 21(35.5%) | 1(7.1%) | 4(12.5%) | .591 | 5(10.8%) |
L linezolid, Mu mupirocin, C chloramphenicol, AK amikacin, FOX cefoxitin, T tetracycline, PG penicillin, CIP ciprofloxacin, GM gentamicin, SXT trimethoprim/sulfamethoxazole, E erythromycin, CD clindamycin, RA rifampin
Prevalence of toxin genes, agr groups, and biofilm formation in S. aureus isolates from the two groups
| Infectious Group | Non-infectious Group | χ2
| MRSA | MSSA | χ2 | Total | |
|---|---|---|---|---|---|---|---|
| tsst-1 | 4(13.3%) | 12(16%) | .732 | 13(23.2%) | 3(6.5%) | .028 | 16(15.2%) |
| pvl | 2(6.6%) | 1(1.33) | .138 | 0 | 3(6.5%) | .047 | 3(2.8%) |
| Eta | 3(10%) | 11(14.6%) | .525 | 7(11.8%) | 7(15.2%) | .616 | 14(13.3%) |
| etb | 3(10%) | 5(6.6%) | .561 | 2(3.3%) | 5(10.8%) | .127 | 7(6.6%) |
| hlaα | 12(40%) | 47(62.6%) | .034 | 38(64.4%) | 21(45.6%) | .055 | 59(56.1%) |
| psmα | 20(66.6%) | 46(61.3%) | .609 | 38(64.4%) | 28(60.8%) | .710 | 66(62.8%) |
| agr | 11(36.6%) | 41(54.6%) | .096 | 25(42.3%) | 27(58.6%) | .097 | 52(49.5%) |
| agr | 9(30%) | 14(18.6%) | .205 | 10(16.9%) | 13(28.2%) | .164 | 23(21.9%) |
| agr | 4(13.3%) | 8(10.6%) | .698 | 11(18.6%) | 1(2.1%) | .008 | 12(11.4%) |
| agr | 3(10%) | 12 (16%) | .427 | 10(16.9%) | 5(10.8%) | .377 | 15(14.2%) |
| 6(20%) | 19(25.3%) | .562 | 19(32.2%) | 6(13%) | .022 | 25(23.8%) | |
| 15(50%) | 44(58.6%) | .419 | 24(40.6%) | 35(76%) | .000 | 59(56.1%) | |
| 6(20%) | 9(12%) | .290 | 13(22%) | 2(4.3%) | .010 | 15(14.2%) | |
| 3(10%) | 3(4%) | .231 | 3(5%) | 3(6.5%) | .757 | 6(5.7%) |
S strong, M moderate, W weak
Primers used in this study
| Primer | Sequence (5′ → 3′) | Size (bp) | Ref. |
|---|---|---|---|
F: GTGAAGATATACCAAGTGATT R: ATGCGCTATAGATTGAAAGGA | 146 | [ | |
| SCC | F: GCTTTAAAGAGTGTCGTTACAGG R: GTTCTCTCATAGTATGACGTCC | 613 | |
| SCC | F: CGTTGAAGATGATGAAGCG R: CGAAATCAATGGTTAATGGACC | 398 | |
| SCC | F: CCATATTGTGTACGATGCG R: CCTTAGTTGTCGTAACAGATCG | 280 | |
| SCC | F: GCCTTATTCGAAGAAACCG R: CTACTCTTCTGAAAAGCGTCG | 776 | |
| SCC | F: TCTGGAATTACTTCAGCTGC R: AAACAATATTGCTCTCCCTC | 493 | |
| SCC | F: ACAATATTTGTATTATCGGAGAGC R: TTGGTATGAGGTATTGCTGG | 200 | |
| SCC | F: CTCAAAATACGGACCCCAATACA R: TGCTCCAGTAATTGCTAAAG | 881 | |
| SCC | F: GAACATTGTTACTTAAATGAGCG R: TGAAAGTTGTACCCTTGACACC | 325 | |
| panF | F: ATGCACATGGTGCACATGC | – | [ |
| R: GTCACAAGTACTATAAGCTGCGAT | 440 | ||
| R: GTATTACTAATTGAAAAGTGCCATAGC | 572 | ||
| R: CTGTTGAAAAAGTCAACTAAAAGCTC | 406 | ||
| R: CGATAATGCCGTAATAC CCG | 588 | ||
F: TTATCGTAAGCCCTTTGTTG R: TAAAGGTAGTTCTATTGGAGTAGG | 398 | [ | |
F: CGGTACTACAGATATTGGAAGC R: TGGTAATCATCACGAACTCG | 744 | [ | |
F: TATCAAAAGCTTAATCGAACAATTC R: CCCCTTCAAATAAGATGTTCATATC | 176 | [ | |
| etA | F: CTAGTG CATTTGTTATTCAAGACG R: TGCATTGACACCATAGTACTTATTC | 119 | [ |
F: ACGGCTATATACATTCAATTAATG R: AAAGTTATTCATTTAATGCACTGTCTC | 200 | [ | |
F: CCTCCCGCACGATGATC R: TCCACGCATCGTCAGGC | 188 | [ |